Rapid Risk Assessment: Plasmid-mediated colistin resistance in Enterobacteriaceae, 15 June 2016
The recently recognised global distribution of a self-transferable plasmid-borne colistin resistance gene (mcr-1) poses a substantial public health risk to the EU/EEA because it further limits treatment options in patients with infections caused by multidrug-resistant gram-negative bacteria. It can spread colistin resistance more easily between bacteria and humans than chromosomal mutation.
MDR gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae strains that acquire the mcr-1 gene, remain susceptible to only a few antimicrobial agents, which means that infections caused by these strains are very difficult to treat.
View and download the maps below.
The recently recognised global distribution of the mcr-1 gene poses a substantial public health risk to the EU/EEA. The gene is widespread in several continents and has been detected in bacteria isolated from multiple different sources such as food-producing animals, food, the environment and humans.
This new mechanism of resistance to colistin is of exceptional public health concern because it further limits treatment options in patients with infections caused by multidrug-resistant (MDR) Gram-negative bacteria, and also because it is a highly mobile type of drug resistance (the gene is on a plasmid) that can spread more easily between bacteria.
MDR Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae strains that acquire the mcr-1gene, remain susceptible to only a few antimicrobial agents, which means that infections caused by these strains are very difficult to treat and result in excess mortality. As the development of new antimicrobials is unlikely to provide a solution anytime soon, it is crucial to take measures to control the spread of mcr-1 and thus protect the activity of colistin.
Although there are still major information gaps, relating to the current prevalence of colistin resistance in human clinical isolates in the EU/EEA, as well as to the historical and current prevalence of colistin resistance due to the mcr-1 gene, the issue of further spread of mcr-1 needs to be taken seriously and be carefully monitored by EU/EEA countries.
Andrea Ammon, ECDC Acting Director, said: “the spread of the mcr-1 gene represents another step towards pandrug resistance and infections that would be very difficult, if not impossible, to treat. Further spread would increase the morbidity and mortality in patients undergoing advanced medical procedures, thus having a profound effect on the practice of medicine.”
In its rapid risk assessment, ECDC outlines a number of actions that need to be considered to reduce identified risks of mcr-1 spread. These include improved laboratory methods for colistin resistance testing and mcr-1detection, improved surveillance, options for appropriate clinical management, and actions to prevent transmission in healthcare settings as well as in the community.
Download: Maps for Plasmid-mediated colistin resistance in Enterobacteriaceae
The recently recognised global distribution of a self-transferable plasmid-borne colistin resistance gene (mcr-1) poses a substantial public health risk to the EU/EEA because it further limits treatment options in patients with infections caused by multidrug-resistant gram-negative bacteria.
Rapid risk assessment: Increase in OXA-244 -producing Escherichia coli in the European Union/European Economic Area and the UK since 2013, first update
20 Jul 2021 - Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
Risk Assessment: Emergence of hypervirulent Klebsiella pneumoniae ST23 carrying carbapenemase genes in EU/EEA countries
17 Mar 2021 - This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
Rapid risk assessment: Outbreak of carbapenemase-producing Enterobacterales in Lithuania, 2019
18 Dec 2019 - Between 1st February and 26th November 2019, 199 cases of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacterales (KPC-CRE) have been detected in Lithuania.